Zimbabwe has rejected a major US health deal valued at 367 million US dollars (£272m) over five years due to Washington's request for confidential information.
The decision came to light after a internal memorandum dated December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesman later stated that the US was demanding access to biological samples for research and commercial gain but was unwilling to share the resulting advantages from future treatments.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had donated more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for further talks to find a deal acceptable to all parties so the nation's critical HIV treatment initiative can be sustained.
Broader Context
Zimbabwe's decision comes after a comparable situation in Kenya, where a high court blocked a similar deal with the US after concerns were filed about the safety of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing government-to-government agreements to boost openness and responsibility.
Based on statements, Sixteen nations in Africa have so far agreed to similar agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Agreement
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation could have provided extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving HIV treatment via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to share its genetic material and health information for a long time, with no corresponding guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"In essence, our country would provide the raw materials for scientific discovery with no certainty that the end products would be available to our population if a future health crisis arise."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were undermining structures previously established through the international organization.
The spokesperson cited its Pathogen Access and Benefit Sharing system designed to manage potential pandemics.
"This mechanism is intended to guarantee that when a nation contributes its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "are not meant as opposition to America," he added.
"We encourage further dialogue with our American counterparts on how future co-operation might be structured in a manner that respects the sovereignty and interests of each country."
Medical Community Reaction
Medical experts said it recognised the government's concerns, but suggested that negotiations should continue given that a large portion of the nation's HIV programmes were funded by foreign aid.
"In cases where technical issues arise, such as those involving data governance or implementation frameworks, these can often be addressed via technical clarification and mutually agreed protections," it said.
The situation underscores the ongoing challenges between accepting much-needed foreign assistance and safeguarding a country's data in an increasingly data-driven world.